Industry News
Biotechnology Industry News
Bayer nabs yet another oncology leader from GSK to bolster cancer efforts
Bayer nabs yet another oncology leader from GSK to bolster cancer efforts gmasson Thu, 04/21/2022 - 15:45
Novavax executives’ pay comes back down to Earth after 8-figure package in 2020
Novavax executives' pay comes back down to Earth after 8-figure package in 2020 aarmstrong Thu, 04/21/2022 - 14:41
Using Knowledge Graphs to Drive Drug Discovery
Using Knowledge Graphs to Drive Drug Discovery ncavazza Thu, 04/21/2022 - 10:05
Who’s who of biopharma execs backs tiny Dutch startup’s bid to treat rare disease
Who’s who of biopharma execs backs tiny Dutch startup’s bid to treat rare disease ntaylor Thu, 04/21/2022 - 08:14
Déjà vu: Ampio’s stock sinks as FDA rejects COVID-19-ravaged osteoarthritis trial
Déjà vu: Ampio's stock sinks as FDA rejects COVID-19-ravaged osteoarthritis trial ntaylor Thu, 04/21/2022 - 06:10
Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership
Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership gmasson Wed, 04/20/2022 - 21:51
Novavax touts early data for flu-COVID combo vaccine as FDA decision looms for single shot
Novavax touts early data for flu-COVID combo vaccine as FDA decision looms for single shot mbayer Wed, 04/20/2022 - 14:12
UPDATE: Aptinyx pauses phase 2 trial of higher dose PTSD med to save cash
UPDATE: Aptinyx pauses phase 2 trial of higher dose PTSD med to save cash mbayer Wed, 04/20/2022 - 11:30
Windtree’s phase 2 shock med rapidly raises blood pressure—and share price
Windtree's phase 2 shock med rapidly raises blood pressure—and share price aarmstrong Wed, 04/20/2022 - 09:34
Arcturus’ stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3
Arcturus' stock sinks after self-amplifying COVID-19 mRNA vaccine posts 55% efficacy in phase 3 ntaylor Wed, 04/20/2022 - 08:20
AbbVie shreds alpha-synuclein Parkinson’s pact on cusp of phase 2, thinning field led by Roche
AbbVie shreds alpha-synuclein Parkinson's pact on cusp of phase 2, thinning field led by Roche ntaylor Wed, 04/20/2022 - 06:55
Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapies
Satellite Bio lifts off with $110M to fuel development of its implantable tissue therapies mbayer Wed, 04/20/2022 - 00:30
Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms
Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms mbayer Tue, 04/19/2022 - 16:29
BioXcel will use $260M finance deal to expand indications for schizophrenia drug
BioXcel will use $260M finance deal to expand indications for schizophrenia drug gmasson Tue, 04/19/2022 - 15:57
Finch’s nest thins out with 20% of employees cut in restructuring after FDA hold
Finch's nest thins out with 20% of employees cut in restructuring after FDA hold aarmstrong Tue, 04/19/2022 - 09:54
Imara eliminates 83% of workforce—including chief medical officer—in wake of pipeline wipeout
Imara eliminates 83% of workforce—including chief medical officer—in wake of pipeline wipeout gmasson Tue, 04/19/2022 - 09:54
Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition
Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition jwaldron Tue, 04/19/2022 - 09:07
Axsome moves ‘closer to judgement day’ for stalled depression therapy
Axsome moves 'closer to judgement day' for stalled depression therapy aarmstrong Tue, 04/19/2022 - 08:54
Moderna’s bivalent beta booster betters Spikevax versus omicron, pointing to promise of variant-specific jabs
Moderna's bivalent beta booster betters Spikevax versus omicron, pointing to promise of variant-specific jabs ntaylor Tue, 04/19/2022 - 08:09
Ouch! Acadia’s non-opioid painkiller flunks midphase test, weakening a potential rival to Vertex
Ouch! Acadia's non-opioid painkiller flunks midphase test, weakening a potential rival to Vertex ntaylor Tue, 04/19/2022 - 04:38